Ensysce Biosciences Inc.
13F holders, Q2 2024 (June 30)10holders +1
4new positions
3sold out
1famous investor
$0.51avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Ensysce Biosciences Inc. in their 13F filings, up 1 from Q1 2024. 4 opened new positions and 3 sold out. The largest holders were Sabby Management, LLC ($159K), Citadel Advisors ($44K) and Geode Capital Management, LLC ($23K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Ensysce Biosciences Inc.
- CUSIP
- 293602405
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $56K |
| Exits | 3 | $18K |
All 13F filers, Q1 2024 → Q2 2024: 222,651 shares bought and 23,189 shares sold, net +199,462 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Sabby Management, LLC | 2.37% | Add +36.4% | 314,353 | $159K |
| Citadel Advisors | 0.00% | New | 86,339 | $44K |
| Geode Capital Management, LLC | 0.00% | Add +151.7% | 46,101 | $23K |
| Vanguard Group Inc. | 0.00% | No change | 18,175 | $9K |
| XTX Topco Ltd | 0.00% | New | 13,236 | $7K |
| Virtu Financial LLC | 0.00% | New | 11,341 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +1.1% | 8,257 | $4K |
| BlackRock Inc. | 0.00% | No change | 975 | $494 |
| Main Street Group, LTD | 0.00% | No change | 370 | $185 |
| Bank of America Corp. | 0.00% | New | 62 | $31 |
"% of holder's portfolio" is ENSYSCE BIOSCIENCES INC's weight in each manager's 13F, not the share of Ensysce Biosciences Inc. the manager owns.